FMP
Mineralys Therapeutics, Inc.
MLYS
NASDAQ
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
13.45 USD
-0.02 (-0.149%)
About
ceo
Mr. Jon Congleton
sector
Healthcare
industry
Biotechnology
website
https://mineralystx.comexchange
NASDAQ
Description
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
CIK
0001933414
ISIN
US6031701013
CUSIP
603170101
Address
150 N. Radnor Chester Rd.
Phone
888-378-6240
Country
US
Employee
28
IPO Date
Feb 10, 2023
Summary
CIK
0001933414
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
603170101
ISIN
US6031701013
Country
US
Price
13.45
Beta
2.46
Volume Avg.
223.14k
Market Cap
667.77M
Shares
-
52-Week
5.85-16.905
DCF
1.36
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-6.17
P/B
-
Website
https://mineralystx.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest MLYS News
It looks like there's no news available.
